MCID: PLM033
MIFTS: 57

Pulmonary Embolism

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pulmonary Embolism

MalaCards integrated aliases for Pulmonary Embolism:

Name: Pulmonary Embolism 11 28 53 5 41 43 14 63 16 71 75 31
Pulmonary Artery Embolism 11
Pulmonary Embolus 11
Pulmonary Emboli 14

Classifications:



External Ids:

Disease Ontology 11 DOID:9477
MeSH 43 D011655
NCIt 49 C50713
SNOMED-CT 68 194882001
ICD10 31 I26 I26.0 I26.9
UMLS 71 C0034065

Summaries for Pulmonary Embolism

MedlinePlus: 41 What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery. It usually happens when a blood clot breaks loose and travels through the bloodstream to the lungs. PE is a serious condition that can cause: Permanent damage to the lungs Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen PE can be life-threatening, especially if a clot is large, or if there are many clots. What causes a pulmonary embolism (PE)? The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lungs. Who is at risk for a pulmonary embolism (PE)? Anyone can get a pulmonary embolism (PE), but certain things can raise your risk of PE: Having surgery, especially joint replacement surgery Certain medical conditions, including Cancers Heart diseases Lung diseases A broken hip or leg bone or other trauma Hormone-based medicines, such as birth control pills or hormone replacement therapy Pregnancy and childbirth. The risk is highest for about six weeks after childbirth. Not moving for long periods, such as being on bed rest, having a cast, or taking a long plane flight Age. Your risk increases as you get older, especially after age 40. Family history and genetics. Certain genetic changes that can increase your risk of blood clots and PE. Obesity What are the symptoms of a pulmonary embolism (PE)? Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. How is a pulmonary embolism (PE) diagnosed? It can be difficult to diagnose PE. To make a diagnosis, your health care provider will: Take your medical history, including asking about your symptoms and risk factors for PE Do a physical exam Run some tests, including various imaging tests and possibly some blood tests What are the treatments for a pulmonary embolism (PE)? If you have PE, you need medical treatment right away. The goal of treatment is to break up clots and help keep other clots from forming. Treatment options include medicines and procedures. Medicines: Anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming. You might get them as an injection, a pill, or through an I.V. (intravenous). They can cause bleeding, especially if you are taking other medicines that also thin your blood, such as aspirin. Thrombolytics are medicines to dissolve blood clots. You may get them if you have large clots that cause severe symptoms or other serious complications. Thrombolytics can cause sudden bleeding, so they are used if your PE is serious and may be life-threatening. Procedures: Catheter-assisted thrombus removal uses a flexible tube to reach a blood clot in your lung. Your health care provider can insert a tool in the tube to break up the clot or to deliver medicine through the tube. Usually you will get medicine to put you to sleep for this procedure. A vena cava filter may be used in some people who cannot take blood thinners. Your health care provider inserts a filter inside a large vein called the vena cava. The filter catches blood clots before they travel to the lungs, which prevents pulmonary embolism. But the filter does not stop new blood clots from forming. Can pulmonary embolism (PE) be prevented? Preventing new blood clots can prevent PE. Prevention may include: Continuing to take blood thinners. It's also important to get regular checkups with your provider, to make sure that the dosage of your medicines is working to prevent blood clots but not causing bleeding. Heart-healthy lifestyle changes, such as heart-healthy eating, exercise, and, if you smoke, quitting smoking Using compression stockings to prevent deep vein thrombosis (DVT) Moving your legs when sitting for long periods of time (such as on long trips) Moving around as soon as possible after surgery or being confined to a bed NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Pulmonary Embolism, also known as pulmonary artery embolism, is related to puerperal pulmonary embolism and lemierre's syndrome, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Embolism is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Phylloquinone and Phenprocoumon have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and bone, and related phenotypes are homeostasis/metabolism and muscle

PubMed Health : 63 Pulmonary embolism: Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus). PE is a serious condition that can:

Disease Ontology: 11 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot.

Wikipedia: 75 Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from... more...

Related Diseases for Pulmonary Embolism

Diseases related to Pulmonary Embolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1480)
# Related Disease Score Top Affiliating Genes
1 puerperal pulmonary embolism 32.4 SERPINC1 F2 F10 APOH
2 lemierre's syndrome 32.3 SERPINC1 F3 F2 CRP
3 polycythemia vera 32.3 VWF SERPINC1 F5 F3 F2 CRP
4 pleural disease 32.2 F3 F2 CRP ALB
5 essential thrombocythemia 32.1 VWF SERPINE1 PLAT ACE
6 antithrombin iii deficiency 32.1 SERPINC1 MTHFR F5 F3 F2 F10
7 cardiogenic shock 32.0 PLAT NPPB
8 pulmonary hypertension 32.0 SERPINE1 NPPB F3 CRP ACE
9 cardiac arrest 31.9 TNNI3 NPPB FABP3 CRP ACE
10 thrombophilia due to thrombin defect 31.9 VWF SERPINE1 SERPINC1 PLAT MTHFR F9
11 protein c deficiency 31.9 SERPINE1 SERPINC1 MTHFR F9 F5 F2
12 respiratory failure 31.8 VWF TNNI3 SERPINE1 SERPINC1 NPPB F3
13 vitamin k deficiency bleeding 31.8 SERPINC1 F9 F3 F2
14 protein s deficiency 31.7 SERPINE1 SERPINC1 MTHFR F5 F3 F2
15 pulmonary disease, chronic obstructive 31.6 NPPB CRP ALB ACE
16 right bundle branch block 31.6 TNNI3 NPPB CRP ACE
17 heparin-induced thrombocytopenia 31.5 F3 F2
18 vascular disease 31.5 VWF SERPINE1 SERPINC1 PLAT MTHFR FGB
19 covid-19 31.5 TNNI3 NPPB F3 F2 CRP ACE
20 varicose veins 31.4 VWF SERPINC1 PLAT MTHFR F5 F2
21 severe acute respiratory syndrome 31.3 F3 CRP ACE
22 acute cor pulmonale 31.3 TNNI3 PLAT NPPB F3 F2 CRP
23 congestive heart failure 31.3 VWF TNNI3 NPPB FABP3 ALB ACE
24 thrombophilia due to activated protein c resistance 31.3 VWF SERPINE1 SERPINC1 MTHFR F9 F5
25 apnea, obstructive sleep 31.3 NPPB CRP ALB ACE
26 pulmonary edema 31.2 TNNI3 SERPINC1 NPPB F2 CRP ACE
27 toxic shock syndrome 31.2 SERPINC1 F3 CRP
28 endocarditis 31.2 TNNI3 SERPINE1 SERPINC1 PLAT F2 CRP
29 heart septal defect 31.2 SERPINC1 NPPB F3 F2 CRP
30 tricuspid valve insufficiency 31.2 TNNI3 PLAT NPPB F3 F2 CRP
31 pericarditis 31.2 TNNI3 NPPB CRP ACE
32 sleep apnea 31.2 SERPINE1 NPPB CRP ALB ACE
33 severe covid-19 31.2 VWF F3 F2 CRP ALB ACE
34 aortic aneurysm 31.1 SERPINE1 F3 F2 CRP ALB ACE
35 infective endocarditis 31.1 VWF NPPB F3 F2 CRP ALB
36 acute kidney failure 31.0 F2 ALB ACE
37 sickle cell anemia 31.0 VWF SERPINC1 F3 F2 CRP ALB
38 polycythemia 31.0 F5 F3 F2 CRP ACE
39 arteriovenous malformation 31.0 VWF PLAT F3 F2 ALB
40 pericardial effusion 31.0 TNNI3 NPPB F3 F2 CRP ALB
41 myocarditis 30.9 TNNI3 NPPB F3 F2 ALB ACE
42 coronary heart disease 1 30.9 SERPINE1 CRP ACE
43 thrombophlebitis 30.9 VWF SERPINF2 SERPINE1 SERPINC1 PLAT MTHFR
44 venous insufficiency 30.9 VWF SERPINE1 PLAT MTHFR F5 F2
45 thrombosis 30.9 VWF SERPINF2 SERPINE1 SERPINC1 PLAT MTHFR
46 inferior myocardial infarction 30.9 TNNI3 PLAT NPPB ACE
47 hyperthyroidism 30.9 VWF F2 CRP ALB
48 third-degree atrioventricular block 30.8 TNNI3 NPPB CRP ACE
49 angina pectoris 30.8 TNNI3 PLAT NPPB F3 CRP ACE
50 atrioventricular block 30.8 TNNI3 NPPB CRP ACE

Graphical network of the top 20 diseases related to Pulmonary Embolism:



Diseases related to Pulmonary Embolism

Symptoms & Phenotypes for Pulmonary Embolism

UMLS symptoms related to Pulmonary Embolism:


hemoptysis; snoring; coughing

GenomeRNAi Phenotypes related to Pulmonary Embolism according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.21 ACE ALB APOH CRP F10 F13A1
2 no effect GR00402-S-2 10.21 ACE ALB APOH CRP F10 F13A1

MGI Mouse Phenotypes related to Pulmonary Embolism:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 ACE ALB APOH CRP F10 F13A1
2 muscle MP:0005369 9.97 ALB F2 F3 FABP3 NPPB PLAT
3 cardiovascular system MP:0005385 9.89 ACE ALB CRP F10 F13A1 F2
4 liver/biliary system MP:0005370 9.86 ACE ALB F5 F9 FABP3 MTHFR
5 mortality/aging MP:0010768 9.55 ACE ALB APOH F10 F13A1 F2

Drugs & Therapeutics for Pulmonary Embolism

PubMed Health treatment related to Pulmonary Embolism: 63

Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies . The main goals of treating PE are to stop the blood clot from getting bigger and keep new clots from forming. Treatment may include medicines to thin the blood and slow its ability to clot. If your symptoms are life threatening, your doctor may give you medicine to quickly dissolve the clot. Rarely, your doctor may use surgery or another procedure to remove the clot.

Drugs for Pulmonary Embolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phylloquinone Approved, Investigational Phase 4 84-80-0 5284607
2
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
3
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
4
Nadroparin Approved, Investigational Phase 4
5
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5282411
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
10
Fluindione Approved, Investigational Phase 4 957-56-2
11
Phenindione Approved, Investigational Phase 4 83-12-5 4760
12
Plasminogen Approved Phase 4 9001-91-6
13
Reviparin Approved, Investigational Phase 4 9041-08-1
14
Tenecteplase Approved Phase 4 191588-94-0
15
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
16
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
17
Dabigatran Approved, Investigational Phase 4 211914-51-1 216210
18
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
19 Menaquinone Investigational Phase 4 1182-68-9
20
Coumarin Experimental Phase 4 91-64-5 323
21
Monteplase Investigational Phase 4 156616-23-8
22
Tezosentan Investigational Phase 4 180384-57-0
23 Pharmaceutical Solutions Phase 4
24 Fibrin fragment D Phase 4
25 Vasodilator Agents Phase 4
26 Respiratory System Agents Phase 4
27 Antioxidants Phase 4
28 Protective Agents Phase 4
29 Vitamins Phase 4
30 Vitamin K Phase 4
31
Naphthoquinone Phase 4
32 Anti-Bacterial Agents Phase 4
33 Sodium Potassium Chloride Symporter Inhibitors Phase 4
34 diuretics Phase 4
35 Trace Elements Phase 4
36 Micronutrients Phase 4
37 Anti-Infective Agents Phase 4
38 Antihypertensive Agents Phase 4
39 Amoxicillin-Potassium Clavulanate Combination Phase 4
40 beta-Lactamase Inhibitors Phase 4
41 Antiviral Agents Phase 4
42 Expectorants Phase 4
43 N-monoacetylcystine Phase 4
44 Antidotes Phase 4
45 Antivitamins K Phase 4
46 Calcium, Dietary Phase 4
47 Liver Extracts Phase 4
48 Fluorodeoxyglucose F18 Phase 4
49 Tissue Plasminogen Activator Phase 4
50 Heparin, Low-Molecular-Weight Phase 4

Interventional clinical trials:

(show top 50) (show all 580)
# Name Status NCT ID Phase Drugs
1 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
2 A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy Unknown status NCT02979561 Phase 4 Dabigatran Etexilate;Warfarin
3 Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism Unknown status NCT00214929 Phase 4
4 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
5 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. Unknown status NCT03129555 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
6 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
7 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
8 Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
9 Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability Completed NCT02132689 Phase 4 Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
10 Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk Completed NCT00381511 Phase 4 low molecular weight heparin
11 Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial) Completed NCT02066662 Phase 4 Rivaroxaban or Marcumar
12 Pharmacokinetic/Pharmacodynamic Study of Monteplase ("Cleactor") in Acute Pulmonary Embolism Completed NCT00442234 Phase 4 Monteplase
13 MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department Completed NCT02584660 Phase 4 Rivaroxaban;Standard-of-care
14 Chemoprophylaxis Plus Early Ambulation Prevent Chinese Thoracic Surgery Patients From Pulmonary Embolism Completed NCT03862755 Phase 4 Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)
15 Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
16 PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study Completed NCT00457158 Phase 4
17 Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive Completed NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
18 Study of the OPTtimum Duration of Acoustic Pulse ThromboLYSis ProcEdure in the Treatment of Acute Submassive Pulmonary Embolism Completed NCT02396758 Phase 4
19 Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism: a Prospective Outcome Study. Completed NCT01134068 Phase 4
20 Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
21 The Cordis Protection From Pulmonary Embolism With the Permanent OptEase™ Filter - A Post Marketing Surveillance Study (PROOF Study) Completed NCT00233740 Phase 4
22 Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography Completed NCT00351754 Phase 4 Isovue
23 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Completed NCT04373707 Phase 4 Enoxaparin
24 Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism:a Multi-Centre, Randomised Controlled Trial in China Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
25 Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing Completed NCT00511173 Phase 4
26 Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00799968 Phase 4 Urokinase
27 Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China Completed NCT00781378 Phase 4 rt-PA
28 Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism Completed NCT01014156 Phase 4 epoprostenol
29 Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid Completed NCT00603317 Phase 4 Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo;Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid
30 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;Placebo
31 Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention Completed NCT00187408 Phase 4 Low Molecular Weight Heparin (dalteparin)
32 N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial Completed NCT02483143 Phase 4 NAC;NaHCO3;Normal Saline
33 D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
34 A Non-Randomized Prospective Study of IVC Filter Retrieval Completed NCT00196118 Phase 4
35 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
36 Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon Completed NCT00586287 Phase 4 Phenprocoumon
37 Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses Completed NCT01828697 Phase 4 Low dose nadroparin;Intermediate dose nadroparin;Low dose enoxaparin;Intermediate dose enoxaparin;Low dose dalteparin;Intermediate dose dalteparin;Fixed low dose tinzaparin;Intermediate dose tinzaparin
38 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
39 Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
40 A Randomized Trial of Ultrasound-facilitated, Catheter-directed, Thrombolysis Versus Anticoagulation for Acute Intermediate-high Risk Pulmonary Embolism: The Higher-risk Pulmonary Embolism Thrombolysis Study Recruiting NCT04790370 Phase 4 Anticoagulation with heparin
41 Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer Recruiting NCT04724460 Phase 4 Long DOAC;Short DOAC
42 Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial Recruiting NCT04263038 Phase 4 Rivaroxaban;Placebo
43 Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness Recruiting NCT02810704 Phase 4 Enteric Coated Aspirin;Warfarin;Rivaroxaban
44 A Multicentre, Randomized Trial of Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism (PRAGUE-26) Recruiting NCT05493163 Phase 4 Thrombolytic;Standard anticoagulation
45 Randomized Controlled Trial of Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Recruiting NCT04168203 Phase 4 Apixaban 2.5 MG;Placebo oral tablet
46 Anti-Xa Concentrations With Continuous Intravenous Infusion and Subcutaneous Administration of Enoxaparin After Coronary Artery Bypass Grafting: Randomized Clinical Trial Recruiting NCT02474212 Phase 4 Enoxaparin
47 PET / CT Scan to Detect Cancer in Patients With Unprovoked Venous Thromboembolic Disease. Open Randomized Clinical Trial. Recruiting NCT03937583 Phase 4 Fludeoxyglucose 18F
48 Pre- vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial Recruiting NCT04731558 Phase 4 enoxaparin or tinzaparin or dalteparin;No intervention
49 Peripheral Low Dose Systemic Thrombolysis Versus Catheter Directed Acoustic Pulse Thrombolysis for Treatment of Submassive Pulmonary Embolism Active, not recruiting NCT03581877 Phase 4 Alteplase
50 Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism Terminated NCT03988842 Phase 4 Alteplase;Unfractionated heparin;Placebo;Apixaban

Search NIH Clinical Center for Pulmonary Embolism

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alteplase
anisindione
Anistreplase
apixaban
Dalteparin
Dalteparin Sodium
danaparoid
Danaparoid sodium
Dicumarol
Enoxaparin
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Papaverine
Papaverine Hydrochloride
Phenprocoumon
rivaroxaban
Streptokinase
tinzaparin
Tinzaparin sodium
Urokinase
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: pulmonary embolism

Genetic Tests for Pulmonary Embolism

Genetic tests related to Pulmonary Embolism:

# Genetic test Affiliating Genes
1 Pulmonary Embolism 28

Anatomical Context for Pulmonary Embolism

Organs/tissues related to Pulmonary Embolism:

MalaCards : Heart, Lung, Bone, Liver, Brain, Spinal Cord, Kidney

Publications for Pulmonary Embolism

Articles related to Pulmonary Embolism:

(show top 50) (show all 34943)
# Title Authors PMID Year
1
New Onset of Diabetes Mellitus and Associated Factors among COVID-19 Patients in COVID-19 Care Centers, Addis Ababa, Ethiopia 2022. 62 41
36420090 2022
2
Incidence and risk factors of clinically important venous thromboembolism in tibial plateau fractures. 41
36424499 2022
3
Predictive models for thromboembolic events in giant cell arteritis: A US veterans health administration population-based study. 41
36439172 2022
4
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. 53 62
20513806 2010
5
Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. 53 62
20007142 2010
6
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. 53 62
20447541 2010
7
Clinical usefulness of prothrombin fragment 1+2 in patients with suspected pulmonary embolism. 53 62
19394681 2010
8
Etanercept and venous thromboembolism: a case series. 53 62
20157435 2010
9
[High-risk factors and clinical pathological analysis in 21 cases of fatal pulmonary embolism]. 53 62
20019774 2009
10
Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. 53 62
19525265 2009
11
Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan. 53 62
19618008 2009
12
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. 53 62
20040816 2009
13
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 53 62
19247590 2009
14
Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. 53 62
19087222 2009
15
N-terminal pro-B-type natriuretic peptide predicts the burden of pulmonary embolism. 53 62
19214022 2009
16
Thrombo-embolic occlusion of the left anterior descending coronary artery complicating left atrial radiofrequency ablation. 53 62
18988653 2009
17
Natriuretic peptides in acute pulmonary embolism: a systematic review. 53 62
18626627 2008
18
B-type natriuretic peptide in acute pulmonary embolism. 53 62
18706401 2008
19
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report]. 53 62
19169978 2008
20
Mechanisms of the factor V Leiden paradox. 53 62
18617648 2008
21
[Massive pulmonary embolism]. 53 62
18775637 2008
22
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. 53 62
18664972 2008
23
B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism. 53 62
17537186 2008
24
Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. 53 62
18657661 2008
25
Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. 53 62
18556626 2008
26
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure]. 53 62
18803142 2008
27
Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. 53 62
18495689 2008
28
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. 53 62
18256058 2008
29
Mycoplasma pneumonia and pulmonary embolism in a child due to acquired prothrombotic factors. 53 62
18041082 2008
30
Recurrent thrombembolic risk in patients with multiple thrombophilic disorders. 53 62
19366087 2008
31
Epidural hematoma following tissue plasminogen activator (tPA) therapy for pulmonary embolism in a pediatric patient with stage IV Burkitt's lymphoma: a case report. 53 62
17854866 2008
32
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. 53 62
18158473 2008
33
Prognostic value of brain natriuretic peptide in acute pulmonary embolism. 53 62
18721456 2008
34
Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. 53 62
17716710 2008
35
[The efficacy of alteplase in pulmonary embolism treatment]. 53 62
18833155 2008
36
Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. 53 62
17507005 2007
37
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. 53 62
17513552 2007
38
Tenecteplase to treat pulmonary embolism in the emergency department. 53 62
17221330 2007
39
Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. 53 62
16814410 2007
40
Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. 53 62
17345160 2007
41
[Value of plasma BNP levels as a prognostic marker in lung and heart disorders]. 53 62
17978918 2007
42
Spotlight on reteplase in thrombotic occlusive disorders. 53 62
17263591 2007
43
Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. 53 62
17145624 2007
44
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. 53 62
17127709 2007
45
Massive pulmonary embolism secondary to anticardiolipin antibody syndrome. 53 62
17256569 2007
46
Heart-type fatty acid-binding proteins (H-FABP): a reliable tool for initial risk stratification of pulmonary embolism? 53 62
17208938 2007
47
Evaluation of B-type natriuretic peptide to predict complicated pulmonary embolism in patients aged 65 years and older: brief report. 53 62
16938601 2006
48
A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C. 53 62
16899129 2006
49
Heparin-induced thrombocytopenia type II: a rare but significant complication of plasma exchange. 53 62
16342191 2006
50
Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor. 53 62
16855059 2006

Variations for Pulmonary Embolism

ClinVar genetic disease variations for Pulmonary Embolism:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PLAT NM_000930.5(PLAT):c.826C>T (p.Pro276Ser) SNV Uncertain Significance
627396 rs367827951 GRCh37: 8:42039518-42039518
GRCh38: 8:42182000-42182000

Expression for Pulmonary Embolism

Search GEO for disease gene expression data for Pulmonary Embolism.

Pathways for Pulmonary Embolism

Pathways related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
2
Show member pathways
12.46 F10 F13A1 F2 F3 F5 F9
3
Show member pathways
12.4 FGB F2 F13A1 F10 CRP ALB
4
Show member pathways
12.15 SERPINC1 F5 F2 ALB
5
Show member pathways
11.86 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
6
Show member pathways
11.67 VWF FGB F2
7 11.34 VWF FGB F2
8
Show member pathways
11.13 F9 F2 F10
9 11.04 PLAT FGB F10
10 10.61 SERPINF2 SERPINE1 PLAT
11
Show member pathways
10.57 F9 F10
12 10.28 FGB F2 F13A1

GO Terms for Pulmonary Embolism

Cellular components related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.56 VWF SERPINF2 SERPINE1 SERPINC1 PLAT FGB
2 extracellular region GO:0005576 10.47 ACE ALB APOH CRP F10 F13A1
3 endoplasmic reticulum lumen GO:0005788 10.21 ALB F10 F2 F5 F9 SERPINC1
4 blood microparticle GO:0072562 10.1 ALB F13A1 F2 FGB SERPINC1 SERPINF2
5 platelet alpha granule lumen GO:0031093 10 ALB F13A1 F5 FGB SERPINE1 SERPINF2
6 collagen-containing extracellular matrix GO:0062023 9.98 APOH F13A1 F2 F3 F9 FGB
7 serine-type endopeptidase complex GO:1905370 9.88 F9 F2 F10
8 extracellular space GO:0005615 9.88 ACE ALB APOH CRP F10 F13A1
9 platelet alpha granule GO:0031091 9.85 VWF FGB F5
10 serine protease inhibitor complex GO:0097180 9.8 SERPINE1 PLAT
11 obsolete intrinsic component of external side of plasma membrane GO:0031233 9.46 F3 F10

Biological processes related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 9.96 F2 FGB PLAT SERPINE1 SERPINF2
2 acute-phase response GO:0006953 9.95 SERPINF2 F2 CRP
3 positive regulation of blood coagulation GO:0030194 9.93 SERPINE1 F2 APOH
4 blood coagulation GO:0007596 9.93 F10 F13A1 F2 F3 F5 F9
5 plasminogen activation GO:0031639 9.88 APOH FGB PLAT
6 negative regulation of plasminogen activation GO:0010757 9.85 SERPINF2 SERPINE1 PLAT
7 negative regulation of fibrinolysis GO:0051918 9.85 SERPINF2 SERPINE1 PLAT F2 APOH
8 blood coagulation, fibrin clot formation GO:0072378 9.8 FGB F13A1
9 regulation of blood coagulation GO:0030193 9.73 APOH F2 SERPINC1
10 regulation of body fluid levels GO:0050878 9.62 F9 F5 F2 F10
11 hemostasis GO:0007599 9.32 F10 F13A1 F2 F3 F5 F9

Molecular functions related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.65 PLAT F9 F3 F2 F10
2 serine-type peptidase activity GO:0008236 9.46 PLAT F9 F2 F10
3 protease binding GO:0002020 9.32 VWF SERPINF2 SERPINE1 SERPINC1 F3

Sources for Pulmonary Embolism

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....